P Sanz

Publications (10)16.53 Total impact

• Article: [Developing a Clinical Performance Measures System for hemodialysis, Quality Group, Spanish Society of Nephrology].

  K López Revuelta, G Barril, C Caramelo, R Delgado, F García López, J García Valdecasas, E Gruss, P Jiménez Almonacid, A Martínez Castelao, J Luis Miguel, [......], M D Del Pino Y Pino, J M Portolés, C Prados, P Sanz, A Tato, F Alvarez Ude, M Angoso, J Aranaz, M D Arenas, S Lorenzo
  Nefrologia: publicacion oficial de la Sociedad Espanola Nefrologia 02/2007; 27(5):542-59. · 1.00 Impact Factor
• Article: [Are specific pre-dialysis clinical visit necessary? Objective: comprehensive care of patients with chronic renal disease (CRD)].

  G Barril, P Sanz, M Ruperto, E Bardón, P Ruiz, R Selgas
  Nefrologia: publicacion oficial de la Sociedad Espanola Nefrologia 02/2006; 26 Suppl 3:33-41. · 1.00 Impact Factor
• Article: [Need of responsible information on modalities of renal replacement therapy].

  R Selgas, E Bardón, Maria P Ruiz, P Sanz, O Celadilla, G Barril
  Nefrologia: publicacion oficial de la Sociedad Espanola Nefrologia 02/2006; 26 Suppl 3:42-5. · 1.00 Impact Factor
• Article: Are specific pre-dialysis clinical visit necessary? Objective: comprehensive care of patients with chronic renal disease (CKD)

  G Barril, P Sanz, M Ruperto, E Bardón, P Ruiz, R Selgas
  Nefrología:. 01/2006; 26:33.
• Article: Intermittent and short daily hemodialysis increase HGF plasma levels and diminish HCV viral load

  G. Barril, J. Bartolome, P. Sanz, E. Buoncristiani, J.A. Traver, R. Selgas, V. Carreno, U. Buoncristiani
  [show abstract] [hide abstract]
  ABSTRACT: Decrease of HCV viral load and HGF plasma levels increase have been related to HD sessions. Beneficial effects of HGF stimulation in HD on the outcome of HCV liver disease have been described. Aim was to analyze potential differences between intermittent (3 × week) and short daily (6 × week) HD, examining differences between HCV+ and – pts. We studied 41 pts from 2 HD centres, 26 on intermittent HD (6 on line HF), 8 HCV+, and 15 on short-daily HD with 4 HCV+ 40 pts used synthetic HD membranes (low-flux and high-flux). Among HCV + we determined viral load by Amplicor (Roche) pre- and post- HD. All pts were studied for HGF levels (ELISA) baseline, 15 min, end, and at start of the following session viral load is significantly higher preHD and decreases over session. High-flux membranes were more efficient in reducing viremia (67% vs 45%), which level was higher pre- and post-HD principally in patients using low-flux membranes. Viremia in DHD is lower than in intermittent (470067.3 ± 663974.5 vs 1015695.5 ± 1202679.0). HCV+HCV−pHGF baseline3261.3 ± 1904.52186.5 ± 815.70.01HGF 15 min8000.0 ± 0.07774.0 ± 1129.8nsHGF end6142.5 ± 2262.34443.7 ± 2515.70.03HGF start3391.0 ± 1680.62311.7 ± 633.60.007HGF at baseline, at the end of the session, and starting the following one was significantly higher in HCV + patients. Maximum increase appears always at 15 min. HGF levels were significantly higher in daily HD than intermittent. Of the 14 patients who showed HGF after session higher than 8000, 8 were HCV+(3 in DHD, 5 high flux), 6 were HCV−(5 DHD and 3 high flux), 14 pts finished HD session with HGF>8000, 8HCV+(3 DHD, 5 high flux) and 6HCV−(5 DHD, 4 high-flux). HGF stimulation appears in daily and intermittent HD, with higher level in the latter; HCV+ showed higher HGF vs negative, independently from the HD frequency; HCV viral load diminishes in all HD sessions, more in those with high-flux membranes. Short-daily HD with high-flux synthetic membranes seems the best option for HCV+ patients, and when performed in home precludes nosocomial transmission.
  Hemodialysis International 01/2005; 9(1):83 - 84. · 1.54 Impact Factor
• Article: Pegylated interferon-alpha2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers.

  G Barril, J A Quiroga, P Sanz, F Rodrìguez-Salvanés, R Selgas, V Carreño
  [show abstract] [hide abstract]
  ABSTRACT: Therapeutics in end-stage renal disease (ESRD) patients undergoing haemodialysis (HD) has to consider potential drug clearance during the dialysis procedure. Pegylated interferon-alpha (PEG-IFN-alpha), a middle-size protein drug active against viral hepatitis, allows convenient once-weekly dosing due to prolonged plasma half-life. To investigate the impact of permeability and dialyser pore size on PEG-IFN-alpha blood levels during experimental HD. Polymethylmetacrylate (PMMA) membrane 1.6 m2 dialysers with three different permeabilities/pore sizes were selected. A 40 kDa PEG-IFN-alpha2a (PEGASYS) was not cleared (< 5%) through low-flux/small pore size (25 A;B3A) and high-flux/middle-large pore size (60 A;BKP) dialysers, and was partially (approximately 15%) through intermediate permeability/large pore size (100 A;BKF) dialysers. In contrast, unmodified 17 kDa IFN-alpha2a(Roferon-A) was removed (65%-95%) through BKP or BKF, but not B3A, PMMA dialysers. Moreover, 12 kDa PEG-IFN-alpha2b(PegIntron) was cleared (40%-80%) through PMMA dialysers with pore sizes > or = 60 angstroms. When B3A or BKP were replaced every hour PEG-IFN-alpha2a plasma levels remained constant throughout three experimental-HD-sessions, but PEG-IFN-alpha2b was cleared partially every BKP replacement. Porosity differ among high-flux dialysers. Neither PEG-IFN-alpha2a nor PEG-IFN-alpha2b were removed after three HD sessions through (27/31/33 A) pore size polysulphone dialysers. Although PEG-IFN-alpha2a was not cleared through middle pore-size (43 A/AN69ST) polyacrylonitrile dialyser, PEG-IFN-alpha2b was partially removed. The pharmacokinetics of Peg-IFN-alpha may vary in a patient on dialysis.
  Alimentary Pharmacology & Therapeutics 07/2004; 20(1):37-44. · 3.77 Impact Factor
• Article: [Evaluation of osteodystrophy parameters in a pre-dialysis unit].

  G Barril, P Sanz, E Bardón, T Andrino, S Cigarrán, A Díaz, R Selgas
  [show abstract] [hide abstract]
  ABSTRACT: A cross-sectional study was developed with 100 of the first-time pre-dialysis patients visiting the Princesa University Hospital's Advanced Chronic Kidney Disease (ACKD) unit, with the aim of analysing various parameters of osteodystrophy at this time. Parameters evaluated were: age, gender, renal function, osteodystrophy serum parameters, comorbidity index (ICED) and the patients' origin to establish correlations between these parameters. Mean iPTH levels were higher irrespective of the patients' origin, and were significantly higher in men than in women, the former also having poorer renal function and higher comorbidity score. The mean levels of calcium, phosphorous, alkaline phosphatase and CO2 did not justify this rise in iPTH. Nutritional parameters NPNA and albumin were adequate in spite of ageing. At early stages of ESRD, iPTH could be elevated and ACKD units play an important part its early detection and subsequent treatment.
  Nefrologia: publicacion oficial de la Sociedad Espanola Nefrologia 02/2003; 23 Suppl 2:43-6. · 1.00 Impact Factor
• Article: [Prognostic significance of programmed dialysis in patients who initiate renal substitutive treatment. Multicenter study in Spain].

  J L Górriz, A Sancho, L M Pallardó, M L Amoedo, M Martín, P Sanz, G Barril, R Selgas, M Salgueira, A Palma, M de la Torre, I Ferreras
  [show abstract] [hide abstract]
  ABSTRACT: The aim of our study was to analyse patient characteristics, mortality and costs, all of them in relation to whether starting dialysis was planned or unplanned. A total of 362 patients (227 male and 135 female) from five hospitals of the National Health System, who were started on chronic renal replacement therapy (RRT) during 1996 and 1997 were included. Patients who were started on RRT after acute renal failure were excluded. We carried out a retrospective analysis of the demographic characteristics, patients' conditions at the time of initiating dialysis and outcome and costs at six and thirty-six months of treatment. Patients were classified as planned (PL-D) or unplanned dialysis (UNPL-D), depending on whether or not the patient had a vascular or peritoneal access ready to use for initiating RRT. One hundred and eighty-six patients (51.4%) started on dialysis in the PL-D group whereas 176 (48.6%) did it as UNPL-D. In this latter group, 135 (37.3% of the total) had previously been monitored by a nephrologist, and 41 (11.3%) initiated dialysis without previous nephrological follow-up. UNPL-D was associated with older age (p < 0.001), non-nephrological follow-up (p < 0.001), diabetes (34.7% vs 22.6%) (p = 0.011), haemodialysis as a first mode of RRT (94.9 vs 81.7%) (p < 0.001), higher comorbidity risk (p < 0.001), dialysis initiation with uraemic symptoms or fluid overload (p < 0.001), increased blood transfusion requirement (p < 0.001) and lower serum albumin (p < 0.001), creatinine clearance (p < 0.001), haemoglobin concentration (p < 0.001), and weight (p = 0.002). In the PL-D group the main primary renal diseases were glomerular and polycystic disease, whereas interstitial and diabetic nephropathy were higher in UNPL-D group (p = 0.005). Multivariate analysis showed that previous non nephrological follow-up, uraemic symptoms, interstitial nephritis as primary renal disease correlated with UNPL-D initiation, and it was followed by choosing haemodialysis as first RRT. UNPL-D was also associated with increased number of days of hospitalization at the initiation of dialysis, and during the first 6 months (p < 0.001), increase of hospitalization days (p = 0.009), and increased 6-month-mortality (10.2% vs 3.2%) (p = 0.015, log rank test), and three-year mortality (24.2 vs 36.9%) (p = 0.006, log rank test). The costs of UNPL-D were fivefold that of the PL-D group. UNPL-D has been associated with worse overall clinical conditions at the initiation of chronic replacement therapy, choosing haemodialysis as first RRT, increased morbi-mortality and subsequent increase of costs.
  Nefrologia: publicacion oficial de la Sociedad Espanola Nefrologia 01/2002; 22(1):49-59. · 1.00 Impact Factor
• Article: Prevalence of hepatitis B, hepatitis C, GB virus C/hepatitis G and TT viruses in predialysis and hemodialysis patients.

  J M López-Alcorocho, G Barril, N Ortiz-Movilla, J A Traver, J Bartolomé, P Sanz, R Selgas, V Carreño
  [show abstract] [hide abstract]
  ABSTRACT: Patients with chronic renal failure on hemodialysis have a high risk of infections with viruses such as hepatitis B (HBV), hepatitis C (HCV), GB virus C/hepatitis G (GBV-C/HGV) and TT (TTV) viruses. The prevalence of HBV, HCV, GBV-C/HGV and TTV in patients with chronic renal failure who are on conservative management before entering into a hemodialysis program (predialysis) in comparison with hemodialyzed patients was studied to elucidate whether the high prevalence of these viruses is influenced by that observed in the predialysis stage. The presence of hepatitis B virus surface antigen (HBsAg), HCV RNA, GBV-C/HGV RNA and TTV DNA was analyzed in sera from 80 patients with chronic renal failure (35 on predialysis and 45 on hemodialysis). HBsAg, HCV RNA, GBV-C/HGV RNA and TTV DNA were detected in one (2.8%), six (17.1%), eight (22.5%) and 16 (45.7%) of the 35 patients on predialysis. Two (5.7%) of these patients were coinfected with HCV and GBV-C/HGV, whereas six (17.1%) had GBV-C/HGV and TTV coinfection. In the 45 hemodialyzed patients, HBsAg, HCV RNA, GBV-C/HGV RNA and TTV DNA were detected in one (2.2%), two (4.4%), seven (15.5%) and 26 (57.7%). One (2.2%) patient had HBV and TTV coinfection, two (4.4%) HCV and TTV coinfection whereas four (8.8%) were coinfected with GBV-C/HGV and TTV. No differences regarding age, gender, previous surgery and number of transfusions were found between infected and uninfected patients within and between both groups. In conclusion, the prevalence of the viruses studied in predialysis may influence their prevalence in dialysis units.
  Journal of Medical Virology 03/2001; 63(2):103-7. · 2.82 Impact Factor
• Source

  Available from: Carmen Bernis

  Article: Antineutrophil cytoplasmic autoantibodies (ANCA) and systemic sclerosis.

  I Carvajal, C Bernis, P Sanz, A Garcia, A Garcia-Vadillo, J A Traver
  Nephrology Dialysis Transplantation 04/1997; 12(3):576-7. · 3.40 Impact Factor